Patents by Inventor John G. Jurcak
John G. Jurcak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7777042Abstract: A composition for binding FKBP proteins is disclosed, along with a method of treating conditions associated with neuronal degeneration, wherein said composition comprises a compound of formula I, wherein, R, R1, R2, R3 and X are as defined herein.Type: GrantFiled: December 6, 2006Date of Patent: August 17, 2010Assignee: Aventis Pharmaceuticals Inc.Inventors: Raymond W. Kosley, Jr., Bruce Baron, Patrick Jimonet, John G. Jurcak, Stephen J. Shimshock, Xu-Yang Zhao, Rosy Sher, Paul J. Mueller, Jennifer Beall, Matthieu Barrague, Joseph W. Guiles
-
Patent number: 7772252Abstract: The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine D3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders.Type: GrantFiled: April 17, 2009Date of Patent: August 10, 2010Assignee: Aventis Pharmaceuticals Inc.Inventors: James Hendrix, Horst Hemmerle, Matthias Urmann, Gregory M Shutske, Joseph T Strupczewski, Kenneth J Bordeau, John G Jurcak, Thaddeus Nieduzak, Sharon A. Jackson, Paul Angell, James P Carey, George Lee, David Fink, Jean-Francois Sabuco, Yulin Chiang, Nicola Collar
-
Publication number: 20090247509Abstract: The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine D3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders.Type: ApplicationFiled: April 17, 2009Publication date: October 1, 2009Applicant: AVENTIS PHARMACEUTICALS INC.Inventors: James A. Hendrix, Horst Hemmerle, Matthias Urmann, Gregory M. Shutske, Joseph T. Strupczewski, Kenneth J. Bordeau, John G. Jurcak, Thaddeus R. Nieduzak, Sharon A. Jackson, Paul Angell, James P. Carey, George Lee, David Fink, Jean-Francois Sabuco, Yulin Chiang, Nicola Collar
-
Patent number: 7550469Abstract: The invention relates to heterocyclic substituted amide derivatives that display selective binding to dopamine D3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders.Type: GrantFiled: December 21, 2006Date of Patent: June 23, 2009Assignee: Aventis Pharmaceuticals Inc.Inventors: James A Hendrix, Joseph T Strupczewski, Kenneth Bordeau, Matthias Urmann, Gregory Shutske, Horst Hemmerle, John G Jurcak, Harpal Gill, Franz J Weiberth, Thaddeus Nieduzak, Sharon Anne Jackson, Xu-Yang Zhao, Paul Justin Mueller
-
Patent number: 7521445Abstract: The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine D3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders.Type: GrantFiled: March 5, 2007Date of Patent: April 21, 2009Assignee: Aventis Pharmaceuticals Inc.Inventors: James Hendrix, Horst Hemmerle, Matthias Urmann, Gregory M Shutske, Joseph T Strupczewski, Kenneth J Bordeau, John G Jurcak, Thaddeus Nieduzak, Sharon A. Jackson, Paul Angell, James P Carey, George Lee, David Fink, Jean-Francois Sabuco, Yulin Chiang, Nicola Collar
-
Publication number: 20080139556Abstract: A composition for binding FKBP proteins is disclosed, along with a method of treating conditions associated with neuronal degeneration, wherein said composition comprises a compound of formula I, wherein, R, R1, R2, R3 and X are as defined herein.Type: ApplicationFiled: December 6, 2006Publication date: June 12, 2008Applicant: AVENTIS PHARMACEUTICALS INC.Inventors: Raymond W. KOSLEY, Bruce Baron, Patrick Jimonet, John G. Jurcak, Stephen J. Shimshock, Xu-yang Zhao, Rosy Sher, Paul J. Mueller, Jennifer Beall, Matthieu Barrague, Joseph W. Guiles
-
Publication number: 20080132481Abstract: This invention discloses and claims a class of indole and benzo(b)thiophene derivatives for use in treating allergy, asthma, rhinitis, dermatitis, B-cell lymphomas, tumors and diseases associated with bacterial, rhinovirus or respiratory syncytial virus (RSV) infections. The compounds of this invention are defined by the Formula (I): wherein X, Y, Z, R1, R2 and R3 are as defined in the specification; or a pharmaceutically acceptable salt thereof. In preferred embodiments of this invention it is also disclosed and claimed that the compounds of this invention are capable of modulating T helper (Th) cells, Th1/Th2, and thereby capable of inhibiting the transcription of interleukin-4 (IL-4) message, IL-4 release or IL-4 production.Type: ApplicationFiled: November 30, 2007Publication date: June 5, 2008Inventors: Sefik S. ALKAN, Robert J. DINERSTEIN, Nicholas J. HRIB, Arun SUBRAMANIAM, John G. JURCAK
-
Patent number: 7253165Abstract: The compounds are of the class of benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives, useful as D4 antagonists. Said compounds are useful for the treatment of medical conditions mediated by inhibition of D4 receptor. These conditions comprise, for example, Attention Deficit Hyperactivity Disorder, Obsessive-Compulsive Disorder, Psychoses, Substance Abuse, Substance Dependence, Parkinson's Disease, Parkinsonism, Tardive Diskinesia, Gilles de la Tourette Syndrome, Conduct Disorder, and Oppositional Defiant Disorder. A further aspect of the invention is to provide a pharmaceutical composition, intermediates, and a method of making said class of compounds.Type: GrantFiled: May 12, 2004Date of Patent: August 7, 2007Assignee: Aventis Pharmaceuticals Inc.Inventors: Gregory M. Shutske, James A. Hendrix, John G. Jurcak, Brian S. Freed, Nicholas J. Hrib, John D. Tomer, IV, Reda G. Hanna
-
Patent number: 7186724Abstract: The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine D3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders.Type: GrantFiled: April 6, 2004Date of Patent: March 6, 2007Assignee: Aventis Pharmaceuticals Inc.Inventors: James A Hendrix, Horst Hemmerle, Matthias Urmann, Gregory M Shutske, Jospeh T Strupczewski, Kenneth J Bordeau, John G Jurcak, Thaddeus Nieduzak, Sharon A Jackson, Paul Angell, James P Carey, George Lee, David Fink, Jean-Fancois Sabuco, Yulin Chiang, Nicola Collar
-
Patent number: 7169925Abstract: This invention discloses and claims a new class of indole derivatives for use in treating allergy, asthma, rhinitis, dermatitis, B-cell lymphomas, tumors and diseases associated with bacterial, rhinovirus or respiratory syncytial virus (RSV) infections. It has now been found that the compounds of this invention are capable of modulating T helper (Th) cells, Th1/Th2, and thereby capable of inhibiting the transcription of interleukin-4 (IL-4) message, IL-4 release or IL-4 production.Type: GrantFiled: April 23, 2003Date of Patent: January 30, 2007Assignee: Aventis Pharmaceuticals Inc.Inventors: Gregory H. Merriman, Philip M. Weintraub, Jeffrey S. Sabol, Ramalinga M. Dharanipragada, Nicholas J. Hrib, John G. Jurcak, Alexandre Gross, Brian Whiteley, Kwon Yon Musick, Joseph T. Klein
-
Patent number: 7091199Abstract: The compounds are of the class of thienoisoxazole phenoxy unsubstituted ethyl and propyl derivatives, useful as D4 antagonists. Said compounds are useful for the treatment of medical conditions mediated by inhibition of D4 receptor. These conditions comprise, for example, Attention Deficit Hyperactivity Disorder, Obsessive-Compulsive Disorder, Psychoses, Substance Abuse, Substance Dependence, Parkinson's Disease, Parkinsonism, Tardive Diskinesia, Gilles de la Tourette Syndrome, Conduct Disorder, and Oppositional Defiant Disorder. A further aspect of the invention is to provide a pharmaceutical composition, intermediates, and a method of making said class of compounds.Type: GrantFiled: September 13, 2000Date of Patent: August 15, 2006Assignee: Aventis Pharmaceuticals Inc.Inventors: George E. Lee, John G. Jurcak, Timothy A. Ayers
-
Publication number: 20040220173Abstract: The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine D3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders.Type: ApplicationFiled: April 6, 2004Publication date: November 4, 2004Applicant: Aventis Pharmaceutical Inc.Inventors: James A. Hendrix, Horst Hemmerle, Matthias Urmann, Gregory M. Shutske, Joseph T. Strupczewski, Kenneth J. Bordeau, John G. Jurcak, Thaddeus R. Nieduzak, Sharon A. Jackson, Paul Angell, James P. Carey, George Lee, David Fink, Jean-Francois Sabuco, Yulin Chiang, Nicola Collar
-
Publication number: 20040030137Abstract: The invention relates to heterocyclic substituted amide derivatives that display selective binding to dopamine D3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders.Type: ApplicationFiled: February 19, 2002Publication date: February 12, 2004Inventors: James A. Hendrix, Joseph T. Strupczewski, Kenneth J. Bordeau, Matthias Urmann, Gregory Shutske, Horst Hemmerle, John G. Jurcak, Harpal Gill, Franz J. Weiberth, Thaddeus R. Nieduzak, Sharon Anne Jackson, Xu-Yang Zhao, Paul Justin Mueller
-
Publication number: 20040010029Abstract: This invention discloses and claims a new class of indole derivatives for use in treating allergy, asthma, rhinitis, dermatitis, B-cell lymphomas, tumors and diseases associated with bacterial, rhinovirus or respiratory syncytial virus (RSV) infections. It has now been found that the compounds of this invention are capable of modulating T helper (Th) cells, Th1/Th2, and thereby capable of inhibiting the transcription of interleukin-4 (IL-4) message, IL-4 release or IL-4 production.Type: ApplicationFiled: April 23, 2003Publication date: January 15, 2004Inventors: Gregory H. Merriman, Philip M. Weintraub, Jeffrey S. Sabol, Ramalinga M. Dharanipragada, Nicholas J. Hrib, John G. Jurcak, Alexandre Gross, Brian Whiteley, Kwon Yon Musick, Joseph T. Klein
-
Publication number: 20040006123Abstract: This invention discloses and claims a class of indole and benzo(b)thiophene derivatives for use in treating allergy, asthma, rhinitis, dermatitis, B-cell lymphomas, tumors and diseases associated with bacterial, rhinovirus or respiratory syncytial virus (RSV) infections.Type: ApplicationFiled: April 23, 2003Publication date: January 8, 2004Inventors: Sefik S. Alkan, Robert J. Dinerstein, Nicholas J. Hrib, Arun Subramaniam, John G. Jurcak
-
Patent number: 5440048Abstract: Novel 1-piperazinyl-2-butenes and -2-butynes, intermediates and processes for the preparation thereof, and methods of treating psychoses utilizing compounds or compositions thereof are disclosed.Type: GrantFiled: May 5, 1994Date of Patent: August 8, 1995Assignee: Hoechst-Roussel Pharmaceuticals IncInventors: Helen H. Ong, Nicholas J. Hrib, Joseph Perez, John G. Jurcak
-
Patent number: 5371087Abstract: There are disclosed compounds of the formula, ##STR1## where n is 0, 1 or 2; A is ##STR2## where X in each occurrence is independently hydrogen, halogen, loweralkyl, hydroxy, nitro, loweralkoxy, amino, cyano, trifluoromethyl or methylthio; Y in each occurrence is independently hydrogen, halogen, loweralkyl, hydroxy, nitro, loweralkoxy, amino cyano, trifluoromethyl or methylthio; m is 1 or 2; k is 1 or 2; R.sub.1 and R.sub.2 are independently hydrogen, loweralkyl, ##STR3## or aryl except that when R.sub.1 is ##STR4## or aryl, R.sub.2 is hydrogen, or alternatively R.sub.1 +R.sub.2 taken together with the carbon atom to which they are attached form a cyclopentane, cyclohexane, cycloheptane, pyran, thiopyran, indan or piperidine ring; R.sub.3 and R.sub.4 are independently hydrogen or loweralkyl, or alternatively R.sub.3 +R.sub.Type: GrantFiled: June 29, 1993Date of Patent: December 6, 1994Assignee: Hoechst-Roussel Pharmaceuticals Inc.Inventors: Nicholas J. Hrib, John G. Jurcak
-
Patent number: 5334715Abstract: Novel 1-piperazinyl-2-butenes and -2-butynes, intermediates and processes for the preparation thereof, and methods of treating psychoses utilizing compounds or compositions thereof are disclosed.Type: GrantFiled: February 1, 1993Date of Patent: August 2, 1994Assignee: Hoechst-Roussel Pharmaceuticals Inc.Inventors: Helen H. Ong, Nicholas J. Hrib, Joseph Perez, John G. Jurcak
-
Patent number: 5272148Abstract: Novel heteroarenylpiperazines, intermediates and processes for the preparation thereof, and methods for treating psychoses utilizing compounds or compositions thereof are disclosed.Type: GrantFiled: September 9, 1992Date of Patent: December 21, 1993Assignee: Hoechst-Roussel Pharmaceuticals IncorporatedInventors: Nicholas J. Hrib, John G. Jurcak
-
Patent number: 5240927Abstract: There are disclosed various compounds of the formula depicted below, ##STR1## where the parameters m, n, p, q, X and R are as defined in the specification, as being useful as antipsychotic agents.Type: GrantFiled: May 19, 1992Date of Patent: August 31, 1993Assignee: Hoechst-Roussel Pharmaceuticals IncorporatedInventors: Nicholas J. Hrib, John G. Jurcak